Contineum Therapeutics (NASDAQ:CTNM) Posts Earnings Results, Misses Expectations By $0.04 EPS

Contineum Therapeutics (NASDAQ:CTNM) issued its quarterly earnings results on Tuesday. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.04), FiscalAI reports.

Contineum Therapeutics Stock Up 1.4%

NASDAQ:CTNM opened at $9.69 on Wednesday. Contineum Therapeutics has a one year low of $6.72 and a one year high of $17.78. The stock has a 50 day moving average price of $12.41 and a 200 day moving average price of $13.51.

Analyst Ratings Changes

CTNM has been the topic of a number of research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Contineum Therapeutics in a report on Thursday, October 15th. JonesTrading increased their target price on shares of Contineum Therapeutics from $24.00 to $30.00 and gave the company a “buy” rating in a research report on Thursday, October 15th. Wall Street Zen cut shares of Contineum Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, September 19th. Royal Bank Of Canada raised their price target on shares of Contineum Therapeutics from $22.00 to $23.00 and gave the stock an “outperform” rating in a research note on Friday, July 31st. Finally, Stifel Nicolaus set a $28.00 price target on shares of Contineum Therapeutics in a research report on Wednesday, September 30th. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Contineum Therapeutics presently has a consensus rating of “Hold” and an average target price of $22.33.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for neurological and neuroinflammatory diseases. The company’s research is centered on restoring nervous-system function and addressing conditions in which inflammation or damage to myelin contributes to disease progression.

Contineum’s lead programs include PIPE-307, an oral, selective M1 muscarinic receptor antagonist being studied for its potential to promote remyelination in multiple sclerosis, and PIPE-791, an oral, central nervous system-penetrant LPA1 antagonist being developed for progressive multiple sclerosis and other fibrotic or neuroinflammatory conditions.